INSUBCONTINENT EXCLUSIVE:
Cadila Healthcare is primarily involved in the manufacture of generic drugs.Cadila Healthcare announced its April-June quarter results for
the financial year 2021-22, reporting a net profit of Rs 587.2 crore on a consolidated basis, compared to Rs 454 crore in the corresponding
quarter last year, marking a growth of 29 per cent year-on-year
company's total revenue from operations in the first quarter of the current fiscal stood at Rs 4,025.4 crore, compared to Rs 3,514.6 crore
in the year-ago period.The Gujarat-based multinational company is primarily involved in the manufacture of generic drugs
treatment of COVID-19, according to a regulatory filing by the company to the stock exchanges.Cadila Healthcare has applied to the Drugs
Controller General of India (DCGI) for an emergency use authorization for ZyCoVD - the world's first plasmid DNA vaccine for human use
and consumer wellness business contributed 50 per cent of consolidated revenues during the April-June quarter
The EBIDTA margin stood at 23.2 percent - an improvement of 140 basis points on a sequential or quarter-on-quarter (QoQ) basis.On Wednesday,
August 11, shares of Cadila Healthcare settled 2.54 per cent lower at Rs 563.65 apiece on the BSE.
